198 related articles for article (PubMed ID: 31581267)
21. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
[TBL] [Abstract][Full Text] [Related]
22. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
[TBL] [Abstract][Full Text] [Related]
23. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
24. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
25. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
27. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
Cho MS; Park CH; Lee S; Park HS
PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
[TBL] [Abstract][Full Text] [Related]
29. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
30. Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.
Frankel D; Nanni-Metellus I; Robaglia-Schlupp A; Tomasini P; Guinde J; Barlesi F; Astoul P; Ouafik L; Amatore F; Secq V; Kaspi E; Roll P
Clin Chem Lab Med; 2018 Apr; 56(5):851-856. PubMed ID: 29306909
[TBL] [Abstract][Full Text] [Related]
31. EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas.
García-Inclán C; López F; Pérez-Escuredo J; Cuesta-Albalad MP; Vivanco B; Centeno I; Balbín M; Suárez C; Llorente JL; Hermsen MA
Cell Oncol (Dordr); 2012 Dec; 35(6):443-50. PubMed ID: 23055340
[TBL] [Abstract][Full Text] [Related]
32. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients.
Crisafulli G; Mussolin B; Cassingena A; Montone M; Bartolini A; Barault L; Martinetti A; Morano F; Pietrantonio F; Sartore-Bianchi A; Siena S; Di Nicolantonio F; Marsoni S; Bardelli A; Siravegna G
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32149725
[TBL] [Abstract][Full Text] [Related]
33. Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients.
Kim Y; Kim J; Lee HD; Jeong J; Lee W; Lee KA
PLoS One; 2013; 8(10):e79014. PubMed ID: 24205362
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
[TBL] [Abstract][Full Text] [Related]
35. Ultrasensitive and quantitative detection of EGFR mutations in plasma samples from patients with non-small-cell lung cancer using a dual PNA clamping-mediated LNA-PNA PCR clamp.
Zhang S; Chen Z; Huang C; Ding C; Li C; Chen J; Zhao J; Miao L
Analyst; 2019 Feb; 144(5):1718-1724. PubMed ID: 30663747
[TBL] [Abstract][Full Text] [Related]
36. An enzymatic on/off switch-mediated assay for KRAS hotspot point mutation detection of circulating tumor DNA.
Wang QL; Zhou CL; Yin YF; Xiao L; Wang Y; Li K
J Clin Lab Anal; 2020 Aug; 34(8):e23305. PubMed ID: 32207862
[TBL] [Abstract][Full Text] [Related]
37. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
[TBL] [Abstract][Full Text] [Related]
38. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients.
Mohamed Suhaimi NA; Foong YM; Lee DY; Phyo WM; Cima I; Lee EX; Goh WL; Lim WY; Chia KS; Kong SL; Gong M; Lim B; Hillmer AM; Koh PK; Ying JY; Tan MH
Mol Oncol; 2015 Apr; 9(4):850-60. PubMed ID: 25605225
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.
Thierry AR; El Messaoudi S; Mollevi C; Raoul JL; Guimbaud R; Pezet D; Artru P; Assenat E; Borg C; Mathonnet M; De La Fouchardière C; Bouché O; Gavoille C; Fiess C; Auzemery B; Meddeb R; Lopez-Crapez E; Sanchez C; Pastor B; Ychou M
Ann Oncol; 2017 Sep; 28(9):2149-2159. PubMed ID: 28911069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
